Related Experiment Video
Updated: Apr 4, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Interleukin-1: from discovery to therapeutic targeting of the first cytokine
Lori Broderick1, Naotomo Kambe2, Hal M Hoffman1
1Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Rady Children's Hospital, San Diego, San Diego, CA, USA.
Abstract:
Interleukin-1 (IL-1) was the first cytokine to be discovered and remains one of the most instructive molecules in immunology, linking fundamental mechanisms of innate immune activation to human inflammatory disease and targeted therapy. While it was initially identified for its relationship to fever in the 1970s, pathologic effects of IL-1 became a cornerstone for our understanding of rare monogenic disorders of autoinflammation in the early 2000s. Since that time, the number of disorders implicating a role for IL-1 has expanded to more complex inborn errors of immunity, as well as more common polygenic disorders diagnosed and treated by the practicing allergologist, including asthma, allergic rhinitis and neutrophilic and atopic dermatoses. In this review, we highlight the historical discovery of IL-1, its involvement in various pathologies, and its role as a therapeutic target, with focus on its role in disorders pertinent to the clinical allergist/immunologist.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inhibitors of Viral Protein Synthesis
The JAK-STAT Signaling Pathway
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

